| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10912183 | Lung Cancer | 2005 | 7 Pages |
Abstract
Treatment with combination celecoxib and docetaxel is a safe regimen with a toxicity profile similar to that of docetaxel alone. Survival data are encouraging compared to historical controls and may prolong time to disease progression compared with single-agent docetaxel.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Francis W. Nugent, Wilson C. Mertens, Stephen Graziano, Nathan Levitan, Rufus Collea, Ajeet Gajra, Janine Marshall, John McCann,